Depression News

Nonbinary youths report more depression and are more likely to attempt self-harm than binary transgender youths, according to study findings published in LGBT Health.

The FDA has cleared a first-of-its-kind prescription digital therapeutic to treat major depressive disorder symptoms as an adjunct to clinician-managed outpatient care in adults who have been prescribed antidepressants.

Parents of children with cancer made mental health visits, including those for anxiety and depression, significantly more often than other parents, according to results published in JAMA Network Open.

More than half of patients with treatment-resistant depression achieved response with a single dose of BPL-003, a benzoate salt formulation of 5-MeO-DMT that is administered intranasally, according to a press release from the manufacturer.

The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.

Body dysmorphic disorder and appearance preoccupation were relatively common among youth, especially adolescent girls, according to a study published in Journal of the American Academy of Child & Adolescent Psychiatry.

The COVID-19 pandemic has had a significant impact on the overall well-being of the health care workforce.

In patients with heart failure or coronary artery disease who also had anxiety and/or depression, treatment for their mental health condition was linked to better clinical outcomes, researchers reported.

Although patients with depression presented with and maintained worse spine disease severity after lumbar spine surgery vs. those without depression, researchers found these groups experienced a similar degree of postoperative improvement.

The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.